Sponsor: Aetum Biotechnologies, Inc. (a wholly owned subsidiary of Orpheon Life Sciences).
Submission Type: Technical Briefing Document for NSRA/OEBP Procurement Review
Date: August 14, 2025
Classification: For Official Use Only (FOUO)
Vysera? (daxerimab) is an investigational, short-acting intramuscular biologic intended for transient suppression of non-volitional superhuman phenotypic expression. Clinical studies demonstrate reliable onset within 25–35 minutes and a mean duration of effect of 4–6 hours. Primary indications under review include recurrent transformation syndromes, uncontrolled emission phenomena, and other involuntary activations presenting safety or containment challenges.
Vysera? is formulated as a sterile suspension containing a donor-derived biologic component processed with proprietary carrier compounds. Preclinical data and early human studies suggest the active complex interacts transiently with the recipient’s endocrine and paracrine signaling environment, producing a reversible dampening of aberrant phenotypic expression pathways. Effect onset corresponds to systemic uptake of the carrier compound, while duration is determined by metabolic clearance. Residual biologic material is inert and undergoes gradual immunologic clearance without systemic sequelae.
Sponsor requests restricted-distribution procurement under NSRA authority for continuation of Phase 2 real-world evidence collection and controlled distribution to qualified participants. Sponsor attests that all source material has been rendered non-replicative.
-
Investigational status: Authorized under IND #DAX-2019-072; IRB oversight confirmed. Local IRB approvals obtained where feasible.
-
Clinical trials: Ongoing Phase 2, open-label, multicenter trial (NCT-0XXXXXXX). Enrollment: 37 participants.
-
Ethical note: Placebo control deemed nonviable given unacceptable risk of uncontrolled activations; historical baselines and within-subject comparisons are employed instead.
-
Oversight: Independent Data Safety Monitoring Board (DSMB) established; quarterly review.
-
Population: Adult participants (18–55) with documented non-volitional phenotypic expression.
-
Design: Open-label, dose-escalation and dose-maintenance cohorts.
-
Primary endpoint: Duration of suppression (defined as absence of activation under trigger conditions). Efficacy endpoints met despite heterogeneity in participant reporting.
Unauthorized reproduction: this story has been taken without approval. Report sightings.
-
Results (interim, n=37):
-
Median onset: 30 min (range 22–38 min).
-
Median duration: 5.1 hrs (SD ±0.6).
-
Suppression rate: 100% of evaluable trigger events suppressed within effect window.
-
-
Safety: Most frequent adverse events: mild injection-site reaction (41%), transient headache (19%), transient dizziness (11%). Rare events: cutaneous cyst formation at injection site (2 participants). No severe adverse events reported to date.
-
Formulation: Sterile injectable suspension, single-use autoinjector, 1 mL.
-
Administration: Intramuscular (deltoid or thigh).
-
Storage: Refrigerated, 2–8°C; shelf life 90 days (ongoing stability studies).
-
Lot release: Batch VY-0901 through VY-0907 available for distribution. Certificate of Analysis appended.
-
Manufacturer: Contract production at Veridian Biologics, Rockville, MD (FDA-inspected cGMP facility).
-
Lot release testing: Identity, potency (HPLC assay), sterility, endotoxin, particulate, and stability.
-
Quality audits: Independent QA audit completed July 2025; no critical observations. Certificate of Analysis attached for representative lots.
-
Chain of custody: All biologic source materials processed in accordance with ethical procurement standards. Full provenance records available for inspection by cleared NSRA auditors. Chain-of-custody documentation reviewed by in-house compliance officer, available for external audit upon request.
-
REMS-style program proposed: restricted distribution, weekly monitoring visits, mandatory biometric bracelet for pharmacovigilance.
-
Pharmacovigilance plan: Adverse events collected via direct reporting and electronic monitoring; expedited reporting to NSRA within 24 hours for serious AEs.
-
Contraindications: Not recommended for pediatric use; reproduction prohibited during participation.
-
Capacity: 1,000 units per 14-day lead time; scalable to 5,000 units/month within existing facility.
-
Distribution: Secure courier with lot tracking and return of unused doses.
-
Price: [Redacted – submitted under separate cost volume].
-
Insurance: Product liability coverage confirmed (policy #AXX-48217), insurer redacted.
-
Indemnification: Sponsor assumes liability for adverse events under IND status; NSRA protected under federal procurement indemnity clauses.
-
Export/Import: Not applicable; all manufacturing domestic.
Primary contact:
Dr. Elaine C. Morhardt, PharmD, RAC
Regulatory & Clinical Affairs Director
Aetum Biotechnologies, Inc.
[Contact information redacted]
Appendices:
-
Appendix A: Interim Clinical Study Report (CSR) extracts.
-
Appendix B: Representative Certificate of Analysis (Lot VY-0903).
-
Appendix C: Independent QA Audit summary.
-
Appendix D: Pharmacovigilance Plan.